
Aris P Agouridis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7060863/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adrenal Aging and Its Implications on Stress Responsiveness in Humans. Frontiers in Endocrinology, 2019, 10, 54.	1.5	112
2	An overview of lipid abnormalities in patients with inflammatory bowel disease. Annals of Gastroenterology, 2011, 24, 181-187.	0.4	67
3	The Effect of Statin Therapy on Arterial Stiffness by Measuring Pulse Wave Velocity: A Systematic Review. Current Vascular Pharmacology, 2010, 8, 638-644.	0.8	59
4	Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?. Review of Diabetic Studies, 2013, 10, 171-190.	0.5	31
5	The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opinion on Pharmacotherapy, 2011, 12, 2605-2611.	0.9	28
6	Statins and their increased risk of inducing diabetes. Expert Opinion on Drug Safety, 2015, 14, 1835-1844.	1.0	27
7	New insights into irritable bowel syndrome: from pathophysiology to treatment. Annals of Gastroenterology, 2019, 32, 554-564.	0.4	25
8	The Effects of Ezetimibe and/or Orlistat on Triglycerideâ€Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients. Lipids, 2010, 45, 445-450.	0.7	23
9	Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. International Journal of Clinical Practice, 2012, 66, 843-853.	0.8	23
10	Ear lobe crease: a marker of coronary artery disease?. Archives of Medical Science, 2015, 6, 1145-1155.	0.4	23
11	High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or nâ€3 Fatty Acids in Mixed Dyslipidemia. Lipids, 2011, 46, 521-528.	0.7	22
12	Combination of Fenofibrate with Non-Statin Drug Regimens. Current Pharmaceutical Design, 2010, 16, 3401-3416.	0.9	21
13	All for Statins and Statins for All; An Update. Current Pharmaceutical Design, 2015, 22, 18-27.	0.9	19
14	Effect of Rosuvastatin Monotherapy and in Combination With Fenofibrate or Omega-3 Fatty Acids on Serum Vitamin D Levels. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 382-386.	1.0	18
15	Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Review of Cardiovascular Therapy, 2011, 9, 355-366.	0.6	16
16	High-density lipoprotein cholesterol: A marker of COVID-19 infection severity?. Atherosclerosis Plus, 2021, 44, 1-9.	0.3	15
17	Strategies to overcome statin intolerance. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 851-855.	1.5	13
18	Is there a role of lipid-lowering therapies in the management of fatty liver disease?. World Journal of Hepatology, 2022, 14, 119-139.	0.8	13

Aris P Agouridis

#	Article	IF	CITATIONS
19	Lomentospora prolificans: An Emerging Opportunistic Fungal Pathogen. Microorganisms, 2022, 10, 1317.	1.6	12
20	Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34 + progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. Atherosclerosis, 2016, 251, 240-247.	0.4	10
21	Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia, 2015, 58, 1960-1961.	2.9	8
22	New-onset extremely low levels of high-density lipoprotein cholesterol. Journal of Clinical Lipidology, 2012, 6, 593-595.	0.6	7
23	Letter to the Editor Dysfunctional high-density lipoprotein: not only quantity but first of all quality?. Archives of Medical Science, 2015, 1, 230-231.	0.4	7
24	The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2021, 33, 312-318.	0.8	7
25	Current lipid-modifying agents. Expert Opinion on Pharmacotherapy, 2015, 16, 1117-1118.	0.9	5
26	Should we consider ezetimibe to reach even lower LDL-C targets?. Current Medical Research and Opinion, 2015, 31, 459-460.	0.9	5
27	Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis. Current Oncology, 2022, 29, 321-336.	0.9	5
28	Comparison of Hemoglobin A _{1c} and Fasting Glucose Criteria to Diagnose Diabetes Among People With Metabolic Syndrome and Fasting Glucose Above 100 mg/dL (5.5 mmol/L). Journal of Clinical Hypertension, 2010, 12, 543-548.	1.0	4
29	Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study. Current Vascular Pharmacology, 2016, 14, 474-480.	0.8	3
30	Aliskiren in Patients with Diabetes: A Systematic Review. Current Vascular Pharmacology, 2012, 10, 140-146.	0.8	3
31	Epicardial adipose tissue deposition in patients with diabetes and renal impairment: Analysis of the literature. World Journal of Diabetes, 2020, 11, 33-41.	1.3	3
32	Statins and Niacin: The End of Residual Risk Therapy?. , 2015, , 37-43.		2
33	Infections Caused by Moellerella wisconsensis: A Case Report and a Systematic Review of the Literature. Microorganisms, 2022, 10, 892.	1.6	2
34	Is brucellosis a great mimic of tuberculosis? A case report. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1711-1715.	1.3	1
35	Anterior Tragal Crease: A Marker of Coronary Artery Disease. Angiology, 2020, 71, 791-792.	0.8	0
36	Hyperemesis Gravidarum: A Benign Condition of Pregnancy or a Challenging Metabolic Disorder?. European Journal of Case Reports in Internal Medicine, 2020, 7, 001979.	0.2	0